<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Fetal growth restriction: Pregnancy management and outcome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Fetal growth restriction: Pregnancy management and outcome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Fetal growth restriction: Pregnancy management and outcome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Giancarlo Mari, MD, MBA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Deborah Levine, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2062436399">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Identification of fetal growth restriction (FGR) is an integral component of prenatal care as it is a leading cause of perinatal morbidity and mortality [
         <a href="#rid1">
          1
         </a>
         ]. When sonographic criteria for diagnosis of FGR are met  (
         <a class="graphic graphic_table graphicRef139438" href="/z/d/graphic/139438.html" rel="external">
          table 1
         </a>
         ), the obstetric provider needs to assess the severity, determine the probable cause, counsel the parents, closely monitor fetal growth and well-being for the remainder of the pregnancy, and determine the optimal time for and route of birth. Management is complicated because FGR is not a homogeneous entity and the cause cannot always be determined prenatally. Regardless of the cause, birth timing needs to balance the consequences of iatrogenic preterm birth with the risk of stillbirth in ongoing monitored pregnancies.
        </p>
        <p>
         This topic will discuss pregnancy management and outcome of FGR in singleton pregnancies. Screening and diagnosis of FGR and evaluation to determine the probable cause are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6752.html" rel="external">
          "Fetal growth restriction: Screening and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6768.html" rel="external">
          "Fetal growth restriction: Evaluation"
         </a>
         .)
        </p>
        <p>
         FGR in twin pregnancies is also reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/130561.html" rel="external">
          "Twin pregnancy: Routine prenatal care", section on 'Screening for fetal growth restriction and discordance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/120803.html" rel="external">
          "Selective fetal growth restriction in monochorionic twin pregnancies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2481337018">
         <span class="h1">
          PRENATAL CARE
         </span>
        </p>
        <p class="headingAnchor" id="H729196846">
         <span class="h2">
          Goal
         </span>
         <span class="headingEndMark">
          —
         </span>
         The focus of prenatal care in pregnancies with FGR is to identify those fetuses who are at highest risk of perinatal demise and thus may benefit from early delivery. Distinguishing the constitutionally small fetus from the fetus with pathologic growth can help avoid unnecessary interventions for the former and lead to appropriate monitoring and delivery timing of the latter. Unfortunately, this distinction is not always possible.
        </p>
        <p class="headingAnchor" id="H578941410">
         <span class="h2">
          Fetal surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The key parameters for fetal surveillance are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Estimated fetal weight (EFW)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Doppler ultrasonography
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal behavior (biophysical profile [BPP] and nonstress test [NST]/cardiotocography [CTG])
        </p>
        <p>
        </p>
        <p>
         Fetal surveillance in FGR is initiated at the gestational age when delivery for perinatal benefit would be considered [
         <a href="#rid2">
          2,3
         </a>
         ]. Patients should receive comprehensive counseling on neonatal morbidity and mortality by a team including the primary obstetric provider, maternal-fetal medicine, and neonatology services before fetal surveillance is initiated, especially when delivery for nonreassuring findings would result in an extremely preterm neonate.
        </p>
        <p>
         The cardiovascular (Doppler) and behavioral (BPP and NST) manifestations of fetal deterioration in FGR can occur largely independent of each other. For example, an abnormal BPP can occur before the appearance of the late Doppler changes (eg, reversed umbilical artery [UA] Doppler flow, ductus venosus [DV] a-wave abnormalities) [
         <a href="#rid4">
          4
         </a>
         ]. This is the reason for monitoring the fetus with multiple modalities. Observational data suggest that adoption of a protocol to detect and monitor FGR can reduce stillbirth [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3277814506">
         <span class="h3">
          Fetal weight
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sonography is performed every two to four weeks to assess the change in EFW over time [
         <a href="#rid2">
          2,3
         </a>
         ]. It is not performed more frequently than every two weeks because the inherent error associated with ultrasonographic measurements can preclude an accurate assessment of interval growth [
         <a href="#rid3">
          3
         </a>
         ]. Continued fetal growth is reassuring, while a fall in the EFW percentile for gestational age is associated with increased perinatal morbidity and mortality  (
         <a class="graphic graphic_figure graphicRef56263" href="/z/d/graphic/56263.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H413366423">
         <span class="h3">
          Doppler ultrasonography, nonstress test/cardiotocography, and biophysical profile
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <strong>
         </strong>
         type
         <strong>
         </strong>
         and frequency of Doppler ultrasound for fetal surveillance to predict adverse neonatal outcome in FGR are not standardized. For example, the Society for Maternal-Fetal Medicine (SMFM), American College of Obstetricians and Gynecologists (ACOG), and American Institute of Ultrasound in Medicine (AIUM) suggest not using Doppler assessment of the DV, middle cerebral artery (MCA), or UA for routine clinical management of FGR [
         <a href="#rid2">
          2
         </a>
         ], whereas the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) supports their use [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Surveillance strategies that incorporate Doppler velocimetry to determine the frequency of fetal behavioral testing (NST/CTG, BPP) are associated with better neonatal outcomes and lower stillbirth rates compared with empirically determined surveillance strategies (stillbirth: 0 to 4 percent versus 8 to 11 percent [
         <a href="#rid9">
          9
         </a>
         ]). The author of this topic monitors UA Doppler in both early- and late-onset FGR (ie, onset &lt;32 versus ≥32 weeks of gestation). In outpatients with late-onset FGR, he also monitors MCA Doppler if the UA Doppler is normal because it may become abnormal before the UA Doppler and this would be an indication to increase the frequency of fetal surveillance. In inpatients, he uses MCA Doppler results as an additional factor to consider during counseling and shared decision-making, but not for delivery timing. Experts do not consistently recommend MCA Doppler in fetal surveillance of FGR because of its low predictive value for adverse perinatal outcome [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The author's protocol is:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the UA and MCA Doppler (if performed because of late-onset FGR) are normal (UA pulsatility index [PI] ≤95
         <sup>
          th
         </sup>
         and MCA PI ≥5
         <sup>
          th
         </sup>
         percentile), then UA and MCA Doppler and a BPP are performed at weekly intervals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If either the UA or MCA Doppler (if performed because of late-onset FGR) is abnormal but the UA has diastolic flow (UA PI &gt;95
         <sup>
          th
         </sup>
         and MCA PI &lt;5
         <sup>
          th
         </sup>
         percentile), amniotic fluid volume is normal, and no concerning maternal or fetal comorbidities exist, then UA and MCA Doppler are performed twice a week and a BPP is also performed at one of the visits and an NST is performed at the other visit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with abnormal UA or MCA Doppler but UA diastolic flow and concerning comorbidities (eg, oligohydramnios, preeclampsia, chronic hypertension) are admitted to the hospital. Following 24-hour inpatient observation and fetal monitoring, care is individualized (inpatient versus outpatient monitoring versus delivery).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the UA Doppler has absent or reversed diastolic flow, then the patient is admitted for convenient access to frequent fetal surveillance and to enable prompt fetal evaluation in the event of decreased fetal activity or other pregnancy complications. NSTs are performed every 6 to 12 hours, a BPP is performed daily, and UA and MCA Doppler are performed two to three times per week.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These fetuses are also monitored with DV Doppler. Absent or reversed DV a-wave in this setting represents an advanced stage of fetal compromise and can be an additional factor to consider during counseling and shared decision-making [
         <a href="#rid4">
          4,11-14
         </a>
         ]; however, this finding alone is not an indication for delivery [
         <a href="#rid15">
          15,16
         </a>
         ]. (See
         <a class="local">
          'Delivery'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H281084016">
         <span class="h2">
          Antenatal corticosteroids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ideally, a course of antenatal
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         (or
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ) is given to pregnancies &lt;34+0 weeks of gestation in the seven days before preterm birth is anticipated. The efficacy of antenatal steroids for reducing neonatal morbidity and mortality in the preterm growth-restricted neonate remains controversial, with two large studies showing conflicting results [
         <a href="#rid17">
          17,18
         </a>
         ]. Until definitive information is available, a course of betamethasone (or dexamethasone) should be administered. The precise day of administration before 34 weeks is based on multiple factors, including the severity of FGR, Doppler findings, comorbid conditions, and rate of deterioration in fetal status. Administration between 34+0 and 36+6 weeks does not appear to decrease the need for respiratory support and increases the rate of neonatal hypoglycemia [
         <a href="#rid19">
          19
         </a>
         ] but is recommended by some guidelines [
         <a href="#rid3">
          3
         </a>
         ]. Administration of antenatal corticosteroids, including potential harms on neurodevelopment, are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">
          "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"
         </a>
         .)
        </p>
        <p>
         Three studies observed that growth-restricted fetuses with absent end-diastolic flow often show transient improvement in blood flow after
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         administration [
         <a href="#rid20">
          20-22
         </a>
         ]. Fetuses that did not show increased flow appeared to have poorer neonatal outcomes. The reason sicker fetuses are unable to mount a vascular response to betamethasone administration is unclear. One action of glucocorticoids is to enhance the tropic effect of catecholamines on heart muscle. It is hypothesized that inotropy does not improve in sicker fetuses because they have impaired cardiac wall compliance.
        </p>
        <p class="headingAnchor" id="H4132184654">
         <span class="h2">
          Maternal interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no convincing evidence that any intervention in an otherwise healthy pregnant patient improves fetal growth and outcome in FGR. Information is available on the following interventions.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nutritional deficiency
         </strong>
         – Patients with risk factors for or with evidence of nutritional deficiencies (eg, pregnancies complicated by bariatric surgery or eating disorders) may benefit from referral to a registered dietician.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Smoking cessation
         </strong>
         – In smokers, an intensive smoking cessation program may be of value in improving fetal growth and has other pregnancy and health benefits [
         <a href="#rid23">
          23,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">
          "Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Statins
         </strong>
         – Use of a statin appears promising. A pilot trial in 38 patients with singleton pregnancies and FGR diagnosed at ≤28 weeks of gestation observed that administration of
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         40 mg improved birth weight compared with no treatment (1300 versus 1040 grams), although the difference was not statistically significant [
         <a href="#rid25">
          25
         </a>
         ]. The pravastatin group had significant improvement in angiogenic profiles but not in Doppler parameters.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antihypertensive therapy
         </strong>
         – In pregnant patients with chronic hypertension, antihypertensive therapy has maternal benefits but neither increases nor clearly decreases the risk of FGR [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phosphodiesterase-5 enzyme inhibitors
         </strong>
         – Use of a phosphodiesterase-5 enzyme inhibitor (eg,
         <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">
          tadalafil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         ) appeared promising and was under investigation [
         <a href="#rid27">
          27
         </a>
         ]. However, a multicenter Dutch trial of sildenafil for treatment of poor prognosis early-onset growth restriction was halted early because of a higher than expected rate of pulmonary hypertension in the intervention group with no benefit in the primary outcome (perinatal mortality or major neonatal morbidity) at the time the trial was stopped [
         <a href="#rid28">
          28
         </a>
         ]. A concurrent trial in Australia and New Zealand reported sildenafil had no effect on fetal growth velocity after diagnosis of growth restriction before 30 weeks but no adverse effects on newborns [
         <a href="#rid29">
          29
         </a>
         ]. In a meta-analysis of phosphodiesterase-5 inhibitors in FGR (six trials using sildenafil, one using tadalafil), the intervention improved uteroplacental, but not fetal cerebral, blood perfusion [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – Numerous other approaches have been tried, including maternal nutritional supplementation (eg, balanced protein energy bars, L-arginine, lipid-based nutrients), oxygen therapy, and interventions to improve blood flow to the placenta (eg, plasma volume expansion,
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         , bed rest, low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , anticoagulation), but the quality of evidence is low and none has been proven effective [
         <a href="#rid31">
          31-40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3037689236">
         <span class="h1">
          DELIVERY
         </span>
        </p>
        <p class="headingAnchor" id="H2701647792">
         <span class="h2">
          General approach to timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is little consensus about the optimal time to deliver the growth-restricted fetus. The timing and route of delivery of pregnancies with FGR is based on a combination of factors, including umbilical artery (UA) Doppler findings, biophysical profile (BPP) score, nonstress test (NST)/cardiotocography (CTG) result, gestational age, and fetal weight.
        </p>
        <p>
         Early severe FGR is a major challenge because morbidity and mortality related to preterm birth are relatively high before 32 weeks [
         <a href="#rid41">
          41,42
         </a>
         ], and between 26 and 29 weeks of gestation each day in utero was estimated to improve survival by 1 to 2 percent in one study [
         <a href="#rid43">
          43
         </a>
         ], and by 50 percent per week in a second study [
         <a href="#rid44">
          44
         </a>
         ]. Although minimum thresholds of 26 weeks of gestation, 500 g, or both have been suggested for delivery for fetal indications, ongoing advances in neonatal care have enabled survival of younger and smaller neonates. Decision-making in these cases is complex and should include coordination of care between maternal-fetal medicine and neonatology services, along with comprehensive patient counseling on neonatal morbidity and mortality and shared decision-making regarding pregnancy management [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The use of 37+0 weeks as the upper threshold for delivery of the least complicated FGR pregnancies is based on very limited data and expert opinion [
         <a href="#rid45">
          45
         </a>
         ]. The increased risk associated with advancing gestational age is supported by a study of over 57,000 pregnancies with estimated fetal weight (EFW) &lt;10
         <sup>
          th
         </sup>
         percentile in which the risk of stillbirth in the 37
         <sup>
          th
         </sup>
         week was 28 in 10,000 and the cumulative risk increased with each advancing week of gestation (38
         <sup>
          th
         </sup>
         week: 41 in 10,000, 39
         <sup>
          th
         </sup>
         week: 77 in 10,000, 40
         <sup>
          th
         </sup>
         week: 194 in 10,000) [
         <a href="#rid46">
          46
         </a>
         ]. This study did not consider the impact of associated factors (eg, amniotic fluid volume, Doppler findings).
        </p>
        <p>
         The use of 30 to 34 weeks as the upper threshold for delivery of the most complicated FGR pregnancies is also based on limited data suggesting that when the UA has absent diastolic flow, the risk of fetal death exceeds neonatal morbidity and mortality rates in pregnancies that are at least 33 to 34 weeks of gestation, and when the UA has reversed diastolic flow, the risk of fetal death exceeds neonatal morbidity and mortality rates in pregnancies that are at least 30 weeks [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Delivery should not be delayed beyond 39+0 weeks of gestation because the risk of fetal demise significantly increases at term, particularly as the severity of FGR increases, without clinically significant neonatal benefit from further maturation in utero. As an example, in a retrospective cohort study, the risk of fetal death at 39 weeks was estimated as 32 per 10,000 ongoing pregnancies for fetal weight
         <sup>
         </sup>
         &lt;3
         <sup>
          rd
         </sup>
         percentile, 23 per 10,000 ongoing pregnancies for fetal weight
         <sup>
         </sup>
         &lt;5
         <sup>
          th
         </sup>
         percentile, 13 per 10,000 ongoing pregnancies for fetal weight &lt;10
         <sup>
          th
         </sup>
         percentile, and 2 per 10,000 ongoing pregnancies for fetal weight ≥10
         <sup>
          th
         </sup>
         percentile [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         The following approach is consistent with major guidelines and is commonly used in the United States. However, it is important to emphasize that the BPP is not universally used and any fetal testing should be interpreted in the specific clinical context [
         <a href="#rid2">
          2,3,9,45
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with a reactive NST and BPP score 8/8, 10/10 or 8/10 with normal amniotic fluid volume:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          UA reversed diastolic flow
         </strong>
         –
         <strong>
         </strong>
         Deliver between 30+0 and 32+0 weeks of gestation or at diagnosis if diagnosed at &gt;32+0 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          UA absent diastolic flow
         </strong>
         – Deliver between 33+0 and 34+0 weeks of gestation or at diagnosis if diagnosed at &gt;34+0 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          UA pulsatility index (PI) abnormal (PI &gt;95
         </strong>
         <strong>
          <sup>
           th
          </sup>
         </strong>
         <strong>
          percentile)
         </strong>
         – Deliver at 37+0 weeks or at diagnosis if diagnosed at &gt;37+0 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          UA PI normal (PI ≤95
         </strong>
         <strong>
          <sup>
           th
          </sup>
         </strong>
         <strong>
          percentile):
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          EFW &lt;3
         </strong>
         <strong>
          <sup>
           rd
          </sup>
         </strong>
         <strong>
          percentile and no comorbidities
         </strong>
         – Deliver at 37+0 weeks or at diagnosis if diagnosed at &gt;37+0 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          EFW ≥3
         </strong>
         <strong>
          <sup>
           rd
          </sup>
         </strong>
         <strong>
          and &lt;10
         </strong>
         <strong>
          <sup>
           th
          </sup>
         </strong>
         <strong>
          percentile and no comorbidities
         </strong>
         – Deliver between 38+0 and 39+0 weeks of gestation or at diagnosis if diagnosed at &gt;39+0 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          FGR with oligohydramnios or comorbidities (eg, preeclampsia, chronic hypertension)
         </strong>
         – Timing should be individualized, but most patients should be delivered between 34+0 and 37+6 weeks of gestation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with nonreassuring fetal testing
         </strong>
         – Management depends on the specific findings and gestational age. In all cases in which delivery for nonreassuring fetal testing is generally indicated but would result in the birth of an extremely preterm neonate, patients should receive comprehensive counseling on neonatal morbidity and mortality by a team including the primary obstetric provider, maternal-fetal medicine, and neonatology services as part of shared decision-making about delivery timing, route of delivery, and neonatal resuscitation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Repetitive late decelerations
         </strong>
         – Prompt delivery is indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          BPP score (BPP includes NST):
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          0 or 2/10:
         </strong>
         This
         <strong>
         </strong>
         is a very abnormal score with a high risk of fetal death without intervention (perinatal mortality within one week: 600 and 125 in 1000, respectively [
         <a href="#rid9">
          9
         </a>
         ]). These pregnancies should be delivered.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          4/10:
         </strong>
         This is an abnormal score (perinatal mortality within one week: 91 in 1000 [
         <a href="#rid9">
          9
         </a>
         ]). The BPP generally should be repeated in one hour. If still 4/10, then delivery is often indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          6/10 with oligohydramnios (mean vertical pocket &lt;2 cm):
         </strong>
         This is also an abnormal score (perinatal mortality within one week: 89 in 1000 [
         <a href="#rid9">
          9
         </a>
         ]). The test should be repeated within 24 hours. The decision to deliver is often individualized based on the results of additional testing (eg, repeat BPP, NST), maternal status, gestational age, and severity of Doppler findings (UA, DV).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          6/10 without oligohydramnios or 8/10 with oligohydramnios (mean vertical pocket &lt;2 cm):
         </strong>
         These are
         <strong>
         </strong>
         equivocal scores (perinatal mortality within one week: variable and 89 in 1000, respectively [
         <a href="#rid9">
          9
         </a>
         ]). The decision to deliver is individualized based on the results of additional testing (eg, NST, repeated BPP), maternal status, gestational age, and severity of Doppler findings (UA, DV).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4287590648">
         <span class="h3">
          Evidence from major trials
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following key randomized trials attempted to answer the question of when to intervene in FGR pregnancies, without a clear conclusion:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <strong>
          Growth Restriction Intervention Trial
         </strong>
         (GRIT) randomly assigned pregnant patients between 24 and 36 weeks with FGR to immediate (n = 273) or delayed (n = 274) delivery if the obstetrician was uncertain about when to intervene [
         <a href="#rid49">
          49
         </a>
         ]. In the delayed delivery group, delivery occurred when the obstetrician was no longer uncertain about intervening, which occurred at a median of 4.9 days from enrollment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The immediate delivery group had fewer stillbirths (2 versus 9 with delayed delivery) but more neonatal and infant deaths (27 versus 18). Follow-up data up to age 13 years showed no differences between groups in cognition, language, motor, or parent-assessed behavior scores on standardized tests [
         <a href="#rid50">
          50,51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These data suggest that delaying delivery of the very preterm growth-restricted fetus in the setting of uncertainty results in some stillbirths, but immediate delivery produces an almost equal number of neonatal deaths, and neither approach results in better long-term neurodevelopmental outcome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <strong>
          Disproportionate Intrauterine Growth Intervention Trial At Term
         </strong>
         trial (DIGITAT) randomly assigned 650 pregnant patients over 36 weeks of gestation with suspected FGR to induction of labor or expectant monitoring [
         <a href="#rid52">
          52-54
         </a>
         ]. The primary outcome was a composite measure of adverse neonatal outcome (death before hospital discharge, five-minute Apgar score &lt;7, UA pH &lt;7.05, or admission to the intensive care unit) [
         <a href="#rid52">
          52
         </a>
         ]. Neonatal morbidity was analyzed separately using Morbidity Assessment Index for Newborns (MAIN) score [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The induction group delivered 10 days earlier and weighed 130 grams less (mean difference -130 grams, 95% CI -188 to -71) than the expectantly managed group, but had statistically similar composite adverse outcome (6.1 versus 5.3 percent with expectant management) and cesarean birth rates (approximately 14 percent) [
         <a href="#rid52">
          52
         </a>
         ]. Developmental and behavioral outcomes at two years of age were also similar for both groups [
         <a href="#rid54">
          54
         </a>
         ]. The authors concluded that both approaches were reasonable, and the choice should depend on patient preference. However, in a subanalysis of data, they reported that neonatal intensive care unit admissions were lower when growth restricted fetuses were delivered after 38 weeks of gestation [
         <a href="#rid53">
          53
         </a>
         ], which suggests a benefit of deferring delivery until 38 weeks of gestation, as long as the fetus is closely monitored and in the absence of other indications for an early delivery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          The Trial of Randomized Umbilical and Fetal Flow in Europe
         </strong>
         <strong>
          (TRUFFLE)
         </strong>
         assessed whether changes in the fetal DV Doppler waveform could be used to guide timing of delivery of FGR instead of CTG short-term variation (STV) [
         <a href="#rid55">
          55
         </a>
         ]. The primary outcome measure was survival without neurodevelopmental impairment at two years of age. Pregnancies were randomly assigned to one of three monitoring approaches: CTG with delivery for reduced STV, DV monitoring with delivery for early DV changes (PI &gt;95
         <sup>
          th
         </sup>
         percentile), or DV monitoring with delivery for late DV changes (a-wave indicating absent or reversed flow). The proportion of infants surviving without neurodevelopmental impairment was 77 to 85 percent, with no significant differences among the three groups. Delaying delivery until the development of late DV changes resulted in an improvement in survival without neurodevelopmental impairment (95 percent versus 91 percent for survivors in the early DV changes group and 85 percent for survivors in the reduced STV group); however, this came at the cost of a small increase in unexpected fetal demise (0 of 166 in the STV group versus 3 of 167 in the early ductal changes group versus 4 of 170 in the late ductal changes group). There were no differences in immediate neonatal composite morbidity or mortality.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a post hoc analysis of their data, the TRUFFLE group concluded both DV and computerized CTG evaluations are warranted since the majority of infants in the DV groups were delivered for reduced STV or spontaneous decelerations in fetal heart rate rather than early or late changes in the DV [
         <a href="#rid56">
          56
         </a>
         ]. The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) practice guidelines on FGR support delivery following 26 weeks of gestation in the presence of DV a-wave at or below baseline [
         <a href="#rid8">
          8
         </a>
         ]. They also recommend delivery between 26+0 and 28+6 weeks in the presence of STV &lt;2.6ms, and between 29+0 and 31+6 weeks in the presence of STV &lt;3.0ms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Caution is urged when extrapolating the above findings to practice in the United States [
         <a href="#rid2">
          2
         </a>
         ] as computerized CTG is not commonly utilized in the United States.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2858987071">
         <span class="h2">
          Route
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cesarean birth is performed for standard obstetric indications; otherwise a trial of labor is acceptable. An unfavorable cervix is not a reason to avoid induction [
         <a href="#rid57">
          57
         </a>
         ]. However,
         <strong>
         </strong>
         when the indication for delivery is reversed flow of the UA, patients are given the option of a scheduled cesarean birth, especially when the cervix is unfavorable, because many of these fetuses will not tolerate labor and it is prudent to avoid adding an acute insult on a chronically hypoxic fetus.
        </p>
        <p>
         We prefer a mechanical ripening method (insertion of a balloon catheter or hygroscopic dilator), which may be safer than prostaglandins in this setting [
         <a href="#rid58">
          58
         </a>
         ]. If the Bishop score is &gt;6, we administer
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         without mechanical ripening.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of observational studies of labor induction with
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9368" href="/z/d/drug information/9368.html" rel="external">
          dinoprostone
         </a>
         , or mechanical methods in FGR, mechanical methods appeared to be associated with a lower occurrence of adverse intrapartum outcomes, but a direct comparison among methods could not be performed [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a secondary analysis of data from the DIGITAT and HYPITAT trials (pregnancies complicated by FGR and hypertension), induction of labor at term in patients with median Bishop scores of 3 (range 1 to 6) was not associated with a higher rate of cesarean birth than expectant management, and approximately 85 percent of patients in both groups achieved a vaginal birth [
         <a href="#rid60">
          60
         </a>
         ]. Prostaglandins or a balloon catheter was used for cervical ripening.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2715530846">
         <span class="h2">
          Intrapartum management
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          Magnesium sulfate
         </a>
         for neuroprotection – Magnesium sulfate is administered for neuroprotection in pregnancies &lt;32 weeks. When studied specifically in pregnancies with growth-restricted fetuses, a decrease in significant neurodevelopmental impairment and death was observed [
         <a href="#rid61">
          61
         </a>
         ]. Dosing and evidence of efficacy are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4481.html" rel="external">
          "Neuroprotective effects of in utero exposure to magnesium sulfate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intrapartum fetal monitoring – Continuous fetal heart rate monitoring is indicated, given the increased potential for fetal hypoxemia during labor.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3110530989">
         <span class="h1">
          OUTCOME/PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The outcome/prognosis of FGR newborns with congenital or genetic abnormalities or congenital infection depends on the specific abnormality. (See separate topic reviews on specific disorders).
        </p>
        <p>
         The outcome/prognosis in other cases is discussed below.
        </p>
        <p class="headingAnchor" id="H633912927">
         <span class="h2">
          Pediatric
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Short-term morbidity and mortality
         </strong>
         – Fetal demise, neonatal death, and neonatal morbidity are more common in FGR than in neonates with birth weights that are appropriate for gestational age [
         <a href="#rid62">
          62
         </a>
         ]. The prognosis worsens with early-onset FGR, increasing severity of FGR  (
         <a class="graphic graphic_figure graphicRef56263" href="/z/d/graphic/56263.html" rel="external">
          figure 1
         </a>
         ), and absent or reversed end-diastolic flow on umbilical artery (UA) Doppler [
         <a href="#rid63">
          63
         </a>
         ]. In a systematic review of studies of FGR diagnosed before 32 weeks of gestation (2895 pregnancies delivered after 2000), the frequencies of fetal and neonatal death were 12 and 8 percent, respectively [
         <a href="#rid64">
          64
         </a>
         ]. The most common neonatal morbidities were respiratory distress syndrome (34 percent), retinopathy of prematurity (13 percent), and sepsis (30 percent). The quality of evidence was generally rated as very low to moderate, except for three large, well-designed, randomized trials. Newborn complications are reviewed in depth separately. (See
         <a class="medical medical_review" href="/z/d/html/5062.html" rel="external">
          "Infants with fetal (intrauterine) growth restriction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term morbidity
         </strong>
         – FGR may predispose to hypertension, type-2 diabetes mellitus, coronary heart disease, and chronic kidney disease in adulthood, which has been attributed to partial resetting of fetal metabolic homeostasis and endocrine systems in response to in utero nutritional deprivation. (See
         <a class="medical medical_review" href="/z/d/html/5062.html" rel="external">
          "Infants with fetal (intrauterine) growth restriction", section on 'Adult chronic disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The combination of preterm birth and severe FGR increases the risk for long-term neurodevelopmental abnormalities and impaired cognitive performance. In the systematic review of studies of FGR diagnosed before 32 weeks of gestation, 476 children underwent neurodevelopmental assessment and 12 percent were diagnosed with cognitive impairment and/or cerebral palsy [
         <a href="#rid64">
          64
         </a>
         ]. These findings should be interpreted cautiously given the small proportion of children with follow-up and differences in patient and pregnancy characteristics among the studies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1263416170">
         <span class="h2">
          Maternal
         </span>
        </p>
        <p class="headingAnchor" id="H4124324464">
         <span class="h3">
          Risk for cardiovascular disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         It has been hypothesized that FGR may be a marker for prepregnancy subclinical maternal cardiovascular impairment. This would explain why the birth of a newborn with FGR unrelated to anatomic or genetic abnormalities appears to be predictive of an increased long-term maternal risk for cardiovascular disease (coronary artery disease, myocardial infarction, coronary revascularization, peripheral arterial disease, transient ischemic attack, stroke). A systematic review of 10 cohort studies found a weak but consistent trend of an increased risk of cardiovascular disease-related morbidity and mortality in patients with a history of birth of a small for gestational age (SGA) newborn compared with those with no such history (odds ratios ranged from 1.09 to 3.50) [
         <a href="#rid65">
          65
         </a>
         ]. Pooling was not performed because of variations in the exposure definition among studies.
        </p>
        <p>
         Whether risk-reduction interventions should be recommended because of a history of FGR is unclear, but healthy lifestyle changes in patients with traditional risk factors for cardiovascular disease (eg, smoking, overweight and obesity, unhealthy diet, physical inactivity) are beneficial. (See
         <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">
          "Overview of primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3206197354">
         <span class="h3">
          Future pregnancies
         </span>
        </p>
        <p class="headingAnchor" id="H1694336151">
         <span class="h4">
          Recurrence risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a tendency to repeat SGA births in successive pregnancies [
         <a href="#rid66">
          66,67
         </a>
         ]. As an example, a prospective national cohort study from the Netherlands reported that the risk of a nonanomalous SGA birth (&lt;5
         <sup>
          th
         </sup>
         percentile) in the second pregnancy of patients whose first birth was SGA versus not SGA was 23 and 3 percent, respectively [
         <a href="#rid66">
          66
         </a>
         ]. The odds of recurrence increase markedly as the number of previous SGA births increases [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         Furthermore, uteroplacental insufficiency may manifest in different ways in different pregnancies. Growth restriction, preterm birth, preeclampsia, abruption, and stillbirth can all be sequelae of impaired placental function. The association between an SGA birth in a first pregnancy and stillbirth in a subsequent pregnancy was illustrated by analysis of data from the Swedish Birth Register  (
         <a class="graphic graphic_table graphicRef56032" href="/z/d/graphic/56032.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid69">
          69
         </a>
         ]; subsequent studies from the United States and Australia reported similar findings [
         <a href="#rid70">
          70,71
         </a>
         ]. The highest risk of stillbirth was in patients with a preterm SGA birth.
        </p>
        <p class="headingAnchor" id="H1632131037">
         <span class="h4">
          Risk reduction in subsequent pregnancies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – In subsequent pregnancies, any potentially treatable causes of suboptimal fetal growth should be addressed (eg, cessation of smoking and alcohol intake, chemoprophylaxis and mosquito avoidance in areas where malaria is prevalent, balanced energy/protein supplementation in patients with significant nutritional deficiencies). (Refer to individual topic reviews).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Avoiding a short interpregnancy interval may also be beneficial as intervals less than 6 to 12 months have been associated with an increased risk of SGA birth [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dietary changes and use of supplements have been evaluated, but the studies generally showed no benefit or had serious design limitations [
         <a href="#rid73">
          73-77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selective role for low-dose
         </strong>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         – Low-dose aspirin may be effective when FGR is secondary to preeclampsia since aspirin appears to reduce the risk of developing preeclampsia in patients at moderate to high risk of developing the disorder. In a meta-analysis of 45 randomized trials of low-dose aspirin for prevention of preeclampsia and FGR in patients at high risk, aspirin prophylaxis markedly reduced the incidence of FGR (relative risk [RR] 0.56, 95% CI 0.44-0.70) compared with placebo/no treatment [
         <a href="#rid78">
          78
         </a>
         ]. Low-dose aspirin is not recommended in the absence of risk factors for preeclampsia [
         <a href="#rid79">
          79
         </a>
         ]. These data are reviewed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">
          "Preeclampsia: Prevention", section on 'Low-dose aspirin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The combination of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and low-molecular-weight heparin (LMWH) was not more effective than aspirin alone in a randomized trial [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No role for anticoagulation
         </strong>
         – Anticoagulation with
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         or LMWH does not reduce the risk of recurrent placenta-mediated late-pregnancy complications, such as growth restriction. In a meta-analysis using individual patient data from randomized trials of LMWH therapy versus no LMWH for patients with any prior placenta-mediated pregnancy complications, the intervention did not significantly reduce the incidence of the primary composite outcome (early-onset or severe preeclampsia, SGA &lt;5
         <sup>
          th
         </sup>
         percentile, abruption, pregnancy loss ≥20 weeks of gestation: 62 of 444 [14 percent] versus 95 of 443 [22 percent], RR 0.64, 95% CI 0.36-1.11) [
         <a href="#rid81">
          81
         </a>
         ]. These data support avoiding anticoagulation in patients with previous placenta-mediated disease, given the lack of clear benefit and potential risks of anticoagulation, cost, and inconvenience.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Selected patients with obstetric antiphospholipid syndrome are an exception. Management of these patients is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6813.html" rel="external">
          "Antiphospholipid syndrome: Obstetric implications and management in pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H928935945">
         <span class="h4">
          Management of subsequent pregnancies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Accurate dating by early ultrasonography is important to establish gestational age, with subsequent intermittent ultrasound examinations to monitor fetal growth. A committee opinion from the American College of Obstetricians and Gynecologists (ACOG) suggests antenatal fetal surveillance in pregnancies after a previous FGR that required a preterm birth [
         <a href="#rid82">
          82
         </a>
         ], based on data that these pregnancies (even if the fetus is an appropriate size for dates) are at increased risk of stillbirth and the risk is inversely related to the gestational age at the first SGA birth [
         <a href="#rid69">
          69,71,83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H482273025">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120349.html" rel="external">
          "Society guideline links: Fetal growth restriction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2064903446">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fetal surveillance
         </strong>
         – The focus of fetal surveillance in pregnancies with fetal growth restriction (FGR) is to identify those fetuses who are at highest risk of perinatal demise and thus may benefit from early delivery. Antenatal surveillance should begin at a gestational age when delivery would be considered for perinatal benefit. The key fetal evaluations are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Growth
         </strong>
         – Serial estimation of estimated fetal weight (EFW) is performed at two- to four-week intervals. (See
         <a class="local">
          'Fetal weight'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitoring
         </strong>
         – The general approach to Doppler and fetal behavioral monitoring is shown in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef141140" href="/z/d/graphic/141140.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Doppler
         </strong>
         – The author monitors umbilical artery (UA) Doppler in both early- and late-onset FGR (ie, onset &lt;32 versus ≥32 weeks of gestation). In outpatients with late-onset FGR with normal UA Doppler, he also monitors middle cerebral artery (MCA) Doppler as it may become abnormal before the UA and would be an indication to increase the frequency of fetal surveillance. Not all centers use MCA Doppler in fetal surveillance of FGR because of its low predictive value for adverse perinatal outcome. The frequency of testing depends on the findings. (See
         <a class="local">
          'Doppler ultrasonography, nonstress test/cardiotocography, and biophysical profile'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Fetal behavior
         </strong>
         <strong>
          (nonstress test [NST]/cardiotocography [CTG] and biophysical profile [BPP])
         </strong>
         – NST/CTG/BPP frequency is based on Doppler results and presence of oligohydramnios or other comorbidities. (See
         <a class="local">
          'Doppler ultrasonography, nonstress test/cardiotocography, and biophysical profile'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing of delivery
         </strong>
         –
         <strong>
         </strong>
         The timing of delivery is based on a combination of factors, including UA Doppler findings, BPP score, NST/CTG result, gestational age, and fetal weight. A course of antenatal
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         (or
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ) is administered to pregnancies &lt;34+0 weeks of gestation in the seven days before preterm birth is anticipated. (See
         <a class="local">
          'General approach to timing'
         </a>
         above and
         <a class="local">
          'Antenatal corticosteroids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delivery route
         </strong>
         – Cesarean birth is performed for standard obstetric indications. If a trial of labor is planned, an unfavorable cervix is not a reason to avoid induction. However,
         <strong>
         </strong>
         when the indication for delivery is reversed flow of the UA, we give patients the option of a scheduled cesarean birth, especially when the cervix is unfavorable, because many of these fetuses will not tolerate labor and we wish to avoid adding more stress on a chronic hypoxic fetus. (See
         <a class="local">
          'Route'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pediatric outcome/prognosis
         </strong>
         – The outcome/prognosis of newborns with anatomic or genetic abnormalities or congenital infection depends on the specific abnormality and are discussed elsewhere. (See separate topic reviews on specific disorders).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fetal demise, neonatal death, and neonatal morbidity are more common in FGR than in neonates with birth weights that are appropriate for gestational age. The prognosis worsens with early-onset FGR, increasing severity of growth restriction  (
         <a class="graphic graphic_figure graphicRef56263" href="/z/d/graphic/56263.html" rel="external">
          figure 1
         </a>
         ), and absent or reversed end-diastolic flow on UA Doppler. Long-term risks include growth abnormalities, impaired neurodevelopment, and increased risk for hypertension, type-2 diabetes mellitus, coronary heart disease, and chronic kidney disease in adulthood. (See
         <a class="local">
          'Pediatric'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal
         </strong>
         <strong>
          outcome/prognosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is a tendency to repeat small for gestational age (SGA) births in successive pregnancies. Furthermore, uteroplacental insufficiency may manifest in different ways in different pregnancies. Growth restriction, preterm birth, preeclampsia, abruption, and stillbirth can all be sequelae of impaired placental function  (
         <a class="graphic graphic_table graphicRef56032" href="/z/d/graphic/56032.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Future pregnancies'
         </a>
         above.).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         may be effective when FGR is secondary to preeclampsia (see
         <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">
          "Preeclampsia: Prevention", section on 'Low-dose aspirin'
         </a>
         ). Anticoagulation with
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         or low-molecular-weight heparin (LMWH) does not reduce the risk of recurrent placenta-mediated late-pregnancy complications, such as growth restriction. (See
         <a class="local">
          'Risk reduction in subsequent pregnancies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The birth of a newborn with FGR may be predictive of an increased long-term maternal risk for cardiovascular disease. Whether risk-reduction interventions should be recommended because of a history of FGR is unclear, but healthy lifestyle changes in patients with traditional risk factors for cardiovascular disease (eg, smoking, overweight and obesity, unhealthy diet, physical inactivity) are beneficial. (See
         <a class="local">
          'Risk for cardiovascular disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">
          "Overview of primary prevention of cardiovascular disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H558291758">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert Resnik, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Resnik R. Intrauterine growth restriction. Obstet Gynecol 2002; 99:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society for Maternal-Fetal Medicine (SMFM). Electronic address:
           <span class="__cf_email__" data-cfemail="b6c6c3d4c5f6c5dbd0db98d9c4d1">
            [email protected]
           </span>
           , Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012). Am J Obstet Gynecol 2020; 223:B2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. Obstet Gynecol 2021; 137:e16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mari G, Hanif F, Kruger M. Sequence of cardiovascular changes in IUGR in pregnancies with and without preeclampsia. Prenat Diagn 2008; 28:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hugh O, Williams M, Turner S, Gardosi J. Reduction of stillbirths in England from 2008 to 2017 according to uptake of the Growth Assessment Protocol: 10-year population-based cohort study. Ultrasound Obstet Gynecol 2021; 57:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stampalija T, Wolf H, Mylrea-Foley B, et al. Reduced fetal growth velocity and weight loss are associated with adverse perinatal outcome in fetuses at risk of growth restriction. Am J Obstet Gynecol 2023; 228:71.e1.
          </a>
         </li>
         <li class="breakAll">
          Manning FA. Intrauterine growth retardation. In: Fetal Medicine: Principles and Practice, Appleton &amp; Lange, Norwalk, CT 1995. p.312.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lees CC, Stampalija T, Baschat A, et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol 2020; 56:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baschat AA, Galan HL, Lee W, et al. The role of the fetal biophysical profile in the management of fetal growth restriction. Am J Obstet Gynecol 2022; 226:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris RK, Say R, Robson SC, et al. Systematic review and meta-analysis of middle cerebral artery Doppler to predict perinatal wellbeing. Eur J Obstet Gynecol Reprod Biol 2012; 165:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baschat AA, Gembruch U, Harman CR. The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. Ultrasound Obstet Gynecol 2001; 18:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrazzi E, Bozzo M, Rigano S, et al. Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus. Ultrasound Obstet Gynecol 2002; 19:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hecher K, Bilardo CM, Stigter RH, et al. Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol 2001; 18:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosmi E, Ambrosini G, D'Antona D, et al. Doppler, cardiotocography, and biophysical profile changes in growth-restricted fetuses. Obstet Gynecol 2005; 106:1240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lalor JG, Fawole B, Alfirevic Z, Devane D. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev 2008; :CD000038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaur S, Picconi JL, Chadha R, et al. Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh &lt;1000 g. Am J Obstet Gynecol 2008; 199:264.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elimian A, Verma U, Canterino J, et al. Effectiveness of antenatal steroids in obstetric subgroups. Obstet Gynecol 1999; 93:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaap AH, Wolf H, Bruinse HW, et al. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Obstet Gynecol 2001; 97:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitar G, Merrill SJ, Sciscione AC, Hoffman MK. Antenatal corticosteroids in the late preterm period for growth-restricted pregnancies. Am J Obstet Gynecol MFM 2020; 2:100153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson MC, Murila F, Tong S, et al. Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus. Obstet Gynecol 2009; 113:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simchen MJ, Alkazaleh F, Adamson SL, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004; 190:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nozaki AM, Francisco RP, Fonseca ES, et al. Fetal hemodynamic changes following maternal betamethasone administration in pregnancies with fetal growth restriction and absent end-diastolic flow in the umbilical artery. Acta Obstet Gynecol Scand 2009; 88:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueras F, Meler E, Eixarch E, et al. Association of smoking during pregnancy and fetal growth restriction: subgroups of higher susceptibility. Eur J Obstet Gynecol Reprod Biol 2008; 138:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aagaard-Tillery KM, Porter TF, Lane RH, et al. In utero tobacco exposure is associated with modified effects of maternal factors on fetal growth. Am J Obstet Gynecol 2008; 198:66.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendoza M, Ferrer-Oliveras R, Bonacina E, et al. Evaluating the Effect of Pravastatin in Early-Onset Fetal Growth Restriction: A Nonrandomized and Historically Controlled Pilot Study. Am J Perinatol 2021; 38:1472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tita AT, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med 2022; 386:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira RDDS, Negrini R, Bernardo WM, et al. The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis. PLoS One 2019; 14:e0219732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pels A, Derks J, Elvan-Taspinar A, et al. Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction: A Randomized Clinical Trial. JAMA Netw Open 2020; 3:e205323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groom KM, McCowan LM, Mackay LK, et al. STRIDER NZAus: a multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction. BJOG 2019; 126:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hessami K, Cozzolino M, Shamshirsaz AA. The effect of phosphodiesterase-5 inhibitors on uteroplacental and fetal cerebral perfusion in pregnancies with fetal growth restriction: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2021; 267:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gülmezoglu AM, Hofmeyr GJ. Bed rest in hospital for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gülmezoglu AM, Hofmeyr GJ. Plasma volume expansion for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gülmezoglu AM, Hofmeyr GJ. Maternal nutrient supplementation for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newnham JP, Godfrey M, Walters BJ, et al. Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial. Aust N Z J Obstet Gynaecol 1995; 35:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gülmezoglu AM, Hofmeyr GJ. Maternal oxygen administration for suspected impaired fetal growth. Cochrane Database Syst Rev 2000; :CD000137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu YH, Shen LY, Zou H, et al. Heparin for patients with growth restricted fetus: a prospective randomized controlled trial. J Matern Fetal Neonatal Med 2010; 23:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gülmezoglu AM, Hofmeyr GJ. Betamimetics for suspected impaired fetal growth. Cochrane Database Syst Rev 2001; :CD000036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pels A, Ganzevoort W, Kenny LC, et al. Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy. Cochrane Database Syst Rev 2023; 7:CD014498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Say L, Gülmezoglu AM, Hofmeyr GJ. Maternal nutrient supplementation for suspected impaired fetal growth. Cochrane Database Syst Rev 2003; :CD000148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinshella MW, Omar S, Scherbinsky K, et al. Effects of Maternal Nutritional Supplements and Dietary Interventions on Placental Complications: An Umbrella Review, Meta-Analysis and Evidence Map. Nutrients 2021; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196:147.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lees C, Marlow N, Arabin B, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol 2013; 42:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baschat AA, Cosmi E, Bilardo CM, et al. Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol 2007; 109:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mari G, Hanif F, Treadwell MC, Kruger M. Gestational age at delivery and Doppler waveforms in very preterm intrauterine growth-restricted fetuses as predictors of perinatal mortality. J Ultrasound Med 2007; 26:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion, Number 831. Obstet Gynecol 2021; 138:e35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trudell AS, Cahill AG, Tuuli MG, et al. Risk of stillbirth after 37 weeks in pregnancies complicated by small-for-gestational-age fetuses. Am J Obstet Gynecol 2013; 208:376.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caradeux J, Martinez-Portilla RJ, Basuki TR, et al. Risk of fetal death in growth-restricted fetuses with umbilical and/or ductus venosus absent or reversed end-diastolic velocities before 34 weeks of gestation: a systematic review and meta-analysis. Am J Obstet Gynecol 2018; 218:S774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilliod RA, Cheng YW, Snowden JM, et al. The risk of intrauterine fetal death in the small-for-gestational-age fetus. Am J Obstet Gynecol 2012; 207:318.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           GRIT Study Group. A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation. BJOG 2003; 110:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thornton JG, Hornbuckle J, Vail A, et al. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. Lancet 2004; 364:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker DM, Marlow N, Upstone L, et al. The Growth Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction. Am J Obstet Gynecol 2011; 204:34.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boers KE, Vijgen SM, Bijlenga D, et al. Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT). BMJ 2010; 341:c7087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boers KE, van Wyk L, van der Post JA, et al. Neonatal morbidity after induction vs expectant monitoring in intrauterine growth restriction at term: a subanalysis of the DIGITAT RCT. Am J Obstet Gynecol 2012; 206:344.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Wyk L, Boers KE, van der Post JA, et al. Effects on (neuro)developmental and behavioral outcome at 2 years of age of induced labor compared with expectant management in intrauterine growth-restricted infants: long-term outcomes of the DIGITAT trial. Am J Obstet Gynecol 2012; 206:406.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lees CC, Marlow N, van Wassenaer-Leemhuis A, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet 2015; 385:2162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visser GHA, Bilardo CM, Derks JB, et al. Fetal monitoring indications for delivery and 2-year outcome in 310 infants with fetal growth restriction delivered before 32 weeks' gestation in the TRUFFLE study. Ultrasound Obstet Gynecol 2017; 50:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werner EF, Savitz DA, Janevic TM, et al. Mode of delivery and neonatal outcomes in preterm, small-for-gestational-age newborns. Obstet Gynecol 2012; 120:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Hafez L, Bicocca MJ, Chauhan SP, Berghella V. Prostaglandins for induction in pregnancies with fetal growth restriction. Am J Obstet Gynecol MFM 2022; 4:100538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Familiari A, Khalil A, Rizzo G, et al. Adverse intrapartum outcome in pregnancies complicated by small for gestational age and late fetal growth restriction undergoing induction of labor with Dinoprostone, Misoprostol or mechanical methods: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020; 252:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernardes TP, Broekhuijsen K, Koopmans CM, et al. Caesarean section rates and adverse neonatal outcomes after induction of labour versus expectant management in women with an unripe cervix: a secondary analysis of the HYPITAT and DIGITAT trials. BJOG 2016; 123:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stockley EL, Ting JY, Kingdom JC, et al. Intrapartum magnesium sulfate is associated with neuroprotection in growth-restricted fetuses. Am J Obstet Gynecol 2018; 219:606.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chauhan SP, Rice MM, Grobman WA, et al. Neonatal Morbidity of Small- and Large-for-Gestational-Age Neonates Born at Term in Uncomplicated Pregnancies. Obstet Gynecol 2017; 130:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delorme P, Kayem G, Lorthe E, et al. Neurodevelopment at 2 years and umbilical artery Doppler in cases of very preterm birth after prenatal hypertensive disorder or suspected fetal growth restriction: EPIPAGE-2 prospective population-based cohort study. Ultrasound Obstet Gynecol 2020; 56:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pels A, Beune IM, van Wassenaer-Leemhuis AG, et al. Early-onset fetal growth restriction: A systematic review on mortality and morbidity. Acta Obstet Gynecol Scand 2020; 99:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grandi SM, Filion KB, Yoon S, et al. Cardiovascular Disease-Related Morbidity and Mortality in Women With a History of Pregnancy Complications. Circulation 2019; 139:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voskamp BJ, Kazemier BM, Ravelli AC, et al. Recurrence of small-for-gestational-age pregnancy: analysis of first and subsequent singleton pregnancies in The Netherlands. Am J Obstet Gynecol 2013; 208:374.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ananth CV, Kaminsky L, Getahun D, et al. Recurrence of fetal growth restriction in singleton and twin gestations. J Matern Fetal Neonatal Med 2009; 22:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhamidipaty-Pelosi S, Fox J, Greer RM, Kumar S. The risk of recurrent small-for-gestational-age infants at term is dependent on the number of previously affected births. Am J Obstet Gynecol 2021; 225:415.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Surkan PJ, Stephansson O, Dickman PW, Cnattingius S. Previous preterm and small-for-gestational-age births and the subsequent risk of stillbirth. N Engl J Med 2004; 350:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salihu HM, Sharma PP, Aliyu MH, et al. Is small for gestational age a marker of future fetal survival in utero? Obstet Gynecol 2006; 107:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon A, Raynes-Greenow C, McGeechan K, et al. Stillbirth risk in a second pregnancy. Obstet Gynecol 2012; 119:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu T, Miao H, Chen Y, et al. Association of Interpregnancy Interval With Adverse Birth Outcomes. JAMA Netw Open 2022; 5:e2216658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crovetto F, Crispi F, Casas R, et al. Effects of Mediterranean Diet or Mindfulness-Based Stress Reduction on Prevention of Small-for-Gestational Age Birth Weights in Newborns Born to At-Risk Pregnant Individuals: The IMPACT BCN Randomized Clinical Trial. JAMA 2021; 326:2150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Middleton P, Gomersall JC, Gould JF, et al. Omega-3 fatty acid addition during pregnancy. Cochrane Database Syst Rev 2018; 11:CD003402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bussières EL, Tarabulsy GM, Pearson J, et al. Maternal prenatal stress and infant birth weight and gestational age: A meta-analysis of prospective studies. Dev Rev 2015; 23:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horvath A, Koletzko B, Szajewska H. Effect of supplementation of women in high-risk pregnancies with long-chain polyunsaturated fatty acids on pregnancy outcomes and growth measures at birth: a meta-analysis of randomized controlled trials. Br J Nutr 2007; 98:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szajewska H, Horvath A, Koletzko B. Effect of n-3 long-chain polyunsaturated fatty acid supplementation of women with low-risk pregnancies on pregnancy outcomes and growth measures at birth: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2006; 83:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216:110.
          </a>
         </li>
         <li class="breakAll">
          American College of Obstetricians and Gynecologists' Practice Advisory: Low-Dose Aspirin Use for the Prevention of Preeclampsia and Related Morbidity and Mortality. December 2021. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/12/low-dose-aspirin-use-for-the-prevention-of-preeclampsia-and-related-morbidity-and-mortality (Accessed on December 21, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groom KM, McCowan LM, Mackay LK, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am J Obstet Gynecol 2017; 216:296.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodger MA, Gris JC, de Vries JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 2016; 388:2629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Indications for Outpatient Antenatal Fetal Surveillance: ACOG Committee Opinion, Number 828. Obstet Gynecol 2021; 137:e177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lykke JA, Paidas MJ, Langhoff-Roos J. Recurring complications in second pregnancy. Obstet Gynecol 2009; 113:1217.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 139556 Version 7.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11864679" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Intrauterine growth restriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32407785" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33481528" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Fetal Growth Restriction: ACOG Practice Bulletin, Number 227.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18438965" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Sequence of cardiovascular changes in IUGR in pregnancies with and without preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32851727" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Reduction of stillbirths in England from 2008 to 2017 according to uptake of the Growth Assessment Protocol: 10-year population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35752304" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Reduced fetal growth velocity and weight loss are associated with adverse perinatal outcome in fetuses at risk of growth restriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35752304" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Reduced fetal growth velocity and weight loss are associated with adverse perinatal outcome in fetuses at risk of growth restriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32738107" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35369904" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The role of the fetal biophysical profile in the management of fetal growth restriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22901972" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Systematic review and meta-analysis of middle cerebral artery Doppler to predict perinatal wellbeing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11844191" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11876805" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11844190" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Monitoring of fetuses with intrauterine growth restriction: a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16319247" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Doppler, cardiotocography, and biophysical profile changes in growth-restricted fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18253968" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Biophysical profile for fetal assessment in high risk pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18771977" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh&lt;1000 g.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9932550" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effectiveness of antenatal steroids in obstetric subgroups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11384702" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33345883" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Antenatal corticosteroids in the late preterm period for growth-restricted pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19300328" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14981365" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19172419" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Fetal hemodynamic changes following maternal betamethasone administration in pregnancies with fetal growth restriction and absent end-diastolic flow in the umbilical artery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18035476" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Association of smoking during pregnancy and fetal growth restriction: subgroups of higher susceptibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18166310" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : In utero tobacco exposure is associated with modified effects of maternal factors on fetal growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32615618" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Evaluating the Effect of Pravastatin in Early-Onset Fetal Growth Restriction: A Nonrandomized and Historically Controlled Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35363951" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Treatment for Mild Chronic Hypertension during Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31339910" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32585017" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30779295" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : STRIDER NZAus: a multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34768119" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The effect of phosphodiesterase-5 inhibitors on uteroplacental and fetal cerebral perfusion in pregnancies with fetal growth restriction: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796093" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Bed rest in hospital for suspected impaired fetal growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796166" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Plasma volume expansion for suspected impaired fetal growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796156" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Maternal nutrient supplementation for suspected impaired fetal growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8717556" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Low dose aspirin for the treatment of fetal growth restriction: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796154" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Maternal oxygen administration for suspected impaired fetal growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19951008" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Heparin for patients with growth restricted fetus: a prospective randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11687064" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Betamimetics for suspected impaired fetal growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37428872" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12535390" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Maternal nutrient supplementation for suspected impaired fetal growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33573262" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effects of Maternal Nutritional Supplements and Dietary Interventions on Placental Complications: An Umbrella Review, Meta-Analysis and Evidence Map.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17306659" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Trends in neonatal morbidity and mortality for very low birthweight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24078432" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17267821" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Predictors of neonatal outcome in early-onset placental dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17459996" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Gestational age at delivery and Doppler waveforms in very preterm intrauterine growth-restricted fetuses as predictors of perinatal mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34259491" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion, Number 831.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23523099" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Risk of stillbirth after 37 weeks in pregnancies complicated by small-for-gestational-age fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29233550" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Risk of fetal death in growth-restricted fetuses with umbilical and/or ductus venosus absent or reversed end-diastolic velocities before 34 weeks of gestation: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23021697" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The risk of intrauterine fetal death in the small-for-gestational-age fetus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12504932" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15302194" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21056403" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The Growth Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21177352" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22342897" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Neonatal morbidity after induction vs expectant monitoring in intrauterine growth restriction at term: a subanalysis of the DIGITAT RCT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22444791" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effects on (neuro)developmental and behavioral outcome at 2 years of age of induced labor compared with expectant management in intrauterine growth-restricted infants: long-term outcomes of the DIGITAT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25747582" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27854382" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Fetal monitoring indications for delivery and 2-year outcome in 310 infants with fetal growth restriction delivered before 32 weeks' gestation in the TRUFFLE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22914464" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Mode of delivery and neonatal outcomes in preterm, small-for-gestational-age newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34813974" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Prostaglandins for induction in pregnancies with fetal growth restriction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32738675" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Adverse intrapartum outcome in pregnancies complicated by small for gestational age and late fetal growth restriction undergoing induction of labor with Dinoprostone, Misoprostol or mechanical methods: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27173131" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Caesarean section rates and adverse neonatal outcomes after induction of labour versus expectant management in women with an unripe cervix: a secondary analysis of the HYPITAT and DIGITAT trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30240651" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Intrapartum magnesium sulfate is associated with neuroprotection in growth-restricted fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28796674" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Neonatal Morbidity of Small- and Large-for-Gestational-Age Neonates Born at Term in Uncomplicated Pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32212388" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Neurodevelopment at 2 years and umbilical artery Doppler in cases of very preterm birth after prenatal hypertensive disorder or suspected fetal growth restriction: EPIPAGE-2 prospective population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31376293" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Early-onset fetal growth restriction: A systematic review on mortality and morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30779636" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Cardiovascular Disease-Related Morbidity and Mortality in Women With a History of Pregnancy Complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23419319" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Recurrence of small-for-gestational-age pregnancy: analysis of first and subsequent singleton pregnancies in The Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19557663" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Recurrence of fetal growth restriction in singleton and twin gestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33848539" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The risk of recurrent small-for-gestational-age infants at term is dependent on the number of previously affected births.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14973215" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Previous preterm and small-for-gestational-age births and the subsequent risk of stillbirth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16582122" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Is small for gestational age a marker of future fetal survival in utero?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22353949" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Stillbirth risk in a second pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35696164" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Association of Interpregnancy Interval With Adverse Birth Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34874420" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effects of Mediterranean Diet or Mindfulness-Based Stress Reduction on Prevention of Small-for-Gestational Age Birth Weights in Newborns Born to At-Risk Pregnant Individuals: The IMPACT BCN Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30480773" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Omega-3 fatty acid addition during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Maternal prenatal stress and infant birth weight and gestational age: A meta-analysis of prospective studies
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17419889" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Effect of supplementation of women in high-risk pregnancies with long-chain polyunsaturated fatty acids on pregnancy outcomes and growth measures at birth: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16762945" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Effect of n-3 long-chain polyunsaturated fatty acid supplementation of women with low-risk pregnancies on pregnancy outcomes and growth measures at birth: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27640943" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27640943" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28153659" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27720497" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34011892" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Indications for Outpatient Antenatal Fetal Surveillance: ACOG Committee Opinion, Number 828.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461415" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Recurring complications in second pregnancy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
